Correction: Research and Development Update

This is a correction to the Research and Development Update announcement published at 7:00am on 24 February 2021 (RNS number 1141Q) which has been amended with the following underlined additions to make it consistent with the French announcement released on Euronext at 8am CET on 24 February 2021. http://novacyt.com/wp-content/uploads/2021/02/Novacyt-RD-Update-24.02.2021-correction-ENGLISH.pdf

Visit Page

Research and Development Update

Paris, France and Camberley, UK – 24 February 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on the progress of its near-term research and development programmes, including the expansion of its product portfolio, clinical trial activity and the publication of independent validations of the Company’s COVID-19

Visit Page

Launch of PCR genotyping assay portfolio to detect COVID-19 variants

Paris, France and Camberley, UK – 2 February 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the launch of a new and innovative portfolio of assays (under the brand name SNPsig®) to aid the diagnosis of the new variants of SARS-CoV-2. http://novacyt.com/wp-content/uploads/2021/02/Novacyt-Variants-launch-02.02.21-ENGLISH.pdf

Visit Page